Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Constellation Pharmaceuticals	Zogenix	Trillium Therapeutics	G1 Therapeutics	Syndax Pharmaceuticals
Symbol	NASDAQ:CNST	NASDAQ:ZGNX	NASDAQ:TRIL	NASDAQ:GTHX	NASDAQ:SNDX
Price Information
Current Price	$20.80	$18.87	$9.59	$20.60	$16.04
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.2	1.7	1.7	1.5	1.8
Analysis Score	3.4	3.4	3.5	3.5	3.4
Community Score	2.4	2.8	2.9	2.4	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	1.7	1.7	2.5
Earnings & Valuation Score	0.0	0.6	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$40.33	$59.00	$21.83	$49.17	$28.27
% Upside from Price Target	93.91% upside	212.67% upside	127.67% upside	138.67% upside	76.26% upside
Trade Information
Market Cap	$996.61 million	$1.05 billion	$988.09 million	$866.40 million	$773.71 million
Beta	2.8	1.6	2.27	2.44	1.8
Average Volume	462,367	797,062	1,441,325	1,405,299	840,847
Sales & Book Value
Annual Revenue	N/A	$3.65 million	$120,000.00	N/A	$1.52 million
Price / Sales	N/A	288.55	8,234.05	N/A	509.02
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$8.23 per share	$5.54 per share	($0.86) per share	$6.80 per share	$1.16 per share
Price / Book	N/A	3.41	-11.15	N/A	13.83
Profitability
Net Income	$-85,550,000.00	$-419,500,000.00	$-41,620,000.00	$-122,450,000.00	$-56,050,000.00
EPS	($3.04)	($3.90)	($1.38)	($3.27)	($1.84)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-8,758.48%	N/A	N/A	-4,656.63%
Return on Equity (ROE)	-28.88%	-53.91%	-70.00%	-49.35%	-77.47%
Return on Assets (ROA)	-24.98%	-36.49%	-28.84%	-41.53%	-52.27%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.05%	N/A	N/A	0.10%	0.15%
Current Ratio	15.81%	4.58%	22.44%	7.45%	11.71%
Quick Ratio	15.81%	4.58%	22.44%	7.45%	11.71%
Ownership Information
Institutional Ownership Percentage	N/A	96.57%	67.46%	77.89%	83.78%
Insider Ownership Percentage	10.60%	3.50%	N/A	14.49%	9.50%
Miscellaneous
Employees	154	218	N/A	122	43
Shares Outstanding	47.91 million	55.81 million	103.03 million	42.06 million	48.24 million
Next Earnings Date	5/10/2021 (Confirmed)	8/4/2021 (Estimated)	8/11/2021 (Estimated)	8/4/2021 (Estimated)	5/11/2021 (Confirmed)
Optionable	Not Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	DAX Stock News Today – Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent – Marketing Sentinel fintechzoom.com - May 8 at 3:00 PM
	Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent marketingsentinel.com - May 8 at 9:59 AM
	Syndax Pharmaceuticals Inc. (SNDX) has great growth outlook for 2021 marketingsentinel.com - May 5 at 10:58 AM
	Syndax Pharmaceuticals (SNDX) to Release Earnings on Tuesday americanbankingnews.com - May 5 at 10:56 AM
	Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 finance.yahoo.com - May 4 at 7:35 AM
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Buy" from Brokerages americanbankingnews.com - May 3 at 2:58 AM
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Here’s What’s Really Going On stocksregister.com - April 26 at 2:50 PM
	Dennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On Shares finance.yahoo.com - April 25 at 8:57 AM
	Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued uk.finance.yahoo.com - April 24 at 8:04 AM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 7.1% After Insider Buying Activity americanbankingnews.com - April 23 at 10:28 AM
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 Shares americanbankingnews.com - April 22 at 7:36 PM
	Pre-earnings Bullish Momentum Pattern and Trigger in Syndax Pharmaceuticals Inc cmlviz.com - April 22 at 3:19 PM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down Following Analyst Downgrade americanbankingnews.com - April 22 at 10:24 AM
	Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last? finance.yahoo.com - April 22 at 10:18 AM
	Wall Street Analyst Initiated Syndax Pharmaceuticals Inc. [SNDX]. What else is Wall St. saying dbtnews.com - April 21 at 11:34 PM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Sees Large Volume Increase americanbankingnews.com - April 21 at 12:58 PM
	46 Biggest Movers From Yesterday msn.com - April 21 at 8:33 AM
	Syndax Pharmaceuticals (NASDAQ:SNDX) PT Lowered to $30.00 at Robert W. Baird americanbankingnews.com - April 21 at 8:28 AM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from B. Riley americanbankingnews.com - April 21 at 8:28 AM
	Syndax Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:SNDX) americanbankingnews.com - April 21 at 4:26 AM
	Why Syndax Pharmaceuticals Stock Is Sinking Today finance.yahoo.com - April 20 at 7:38 PM
	31 Stocks Moving In Tuesday's Mid-Day Session msn.com - April 20 at 2:38 PM
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analyst View Looks Different Today marketingsentinel.com - April 20 at 2:38 PM
	Syndax Lower as Blood Cancer Drug Trial Disappoints Investors finance.yahoo.com - April 20 at 2:38 PM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up to $19.38 americanbankingnews.com - April 20 at 11:36 AM

Date	Company	Brokerage	Action
4/7/2021	Constellation Pharmaceuticals	Royal Bank of Canada	Reiterated Rating
1/25/2021	Constellation Pharmaceuticals	BMO Capital Markets	Upgrade
9/24/2020	Constellation Pharmaceuticals	Oppenheimer	Reiterated Rating
9/3/2020	Constellation Pharmaceuticals	Brookline Capital Management	Initiated Coverage
8/9/2020	Constellation Pharmaceuticals	Jefferies Financial Group	Reiterated Rating
8/6/2020	Constellation Pharmaceuticals	HC Wainwright	Reiterated Rating
6/24/2020	Constellation Pharmaceuticals	JMP Securities	Initiated Coverage
3/11/2020	Constellation Pharmaceuticals	Robert W. Baird	Lower Price Target
3/11/2020	Constellation Pharmaceuticals	Cowen	Reiterated Rating
2/13/2020	Constellation Pharmaceuticals	SunTrust Banks	Initiated Coverage
12/14/2020	Zogenix	Needham & Company LLC	Reiterated Rating
12/2/2020	Zogenix	Mizuho	Reiterated Rating
8/24/2020	Zogenix	Raymond James	Initiated Coverage
8/6/2020	Zogenix	Northland Securities	Reiterated Rating
6/26/2020	Zogenix	William Blair	Reiterated Rating
5/5/2020	Zogenix	Piper Sandler	Lower Price Target
3/5/2020	Zogenix	Citigroup	Initiated Coverage
2/28/2020	Zogenix	LADENBURG THALM/SH SH	Reiterated Rating
2/14/2020	Zogenix	Stifel Nicolaus	Reiterated Rating
1/21/2020	Zogenix	Guggenheim	Reiterated Rating
12/6/2019	Zogenix	Piper Jaffray Companies	Reiterated Rating
4/29/2021	Trillium Therapeutics	Bloom Burton	Upgrade
4/26/2021	Trillium Therapeutics	Jonestrading	Reiterated Rating
4/20/2021	Trillium Therapeutics	Benchmark	Initiated Coverage
11/18/2020	Trillium Therapeutics	Craig Hallum	Boost Price Target
10/12/2020	Trillium Therapeutics	Evercore ISI	Initiated Coverage
8/20/2020	G1 Therapeutics	Wedbush	Reiterated Rating
6/26/2020	G1 Therapeutics	Roth Capital	Initiated Coverage
5/12/2020	G1 Therapeutics	JPMorgan Chase & Co.	Lower Price Target
1/7/2020	G1 Therapeutics	BTIG Research	Boost Price Target
4/21/2021	Syndax Pharmaceuticals	B. Riley	Reiterated Rating
12/8/2020	Syndax Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/8/2020	Syndax Pharmaceuticals	Smith Barney Citigroup	Boost Price Target
12/7/2020	Syndax Pharmaceuticals	Morgan Stanley	Boost Price Target
12/7/2020	Syndax Pharmaceuticals	Barclays	Boost Price Target
5/25/2020	Syndax Pharmaceuticals	Nomura	Reiterated Rating
3/26/2020	Syndax Pharmaceuticals	Nomura Securities	Reiterated Rating

(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources